--- title: "Assessing Idorsia (SWX:IDIA) Valuation After CEO Resignation And Leadership Transition" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280086992.md" description: "Idorsia (SWX:IDIA) is in the spotlight following CEO Dr. Srishti Gupta's resignation, with Chairman Jean Paul Clozel stepping in as interim CEO. The company's share price is currently CHF3.15, significantly below the analyst target of CHF4.50, indicating it may be undervalued. Despite a recent 2.27% increase, the stock has seen a 14.75% decline over the past month. Investors are divided between optimism about future growth and concerns over rising costs and cash needs. A detailed analysis of Idorsia's financial outlook and risks is recommended for potential investors." datetime: "2026-03-23T02:32:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280086992.md) - [en](https://longbridge.com/en/news/280086992.md) - [zh-HK](https://longbridge.com/zh-HK/news/280086992.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280086992.md) | [English](https://longbridge.com/en/news/280086992.md) # Assessing Idorsia (SWX:IDIA) Valuation After CEO Resignation And Leadership Transition Idorsia (SWX:IDIA) is back in focus after announcing that CEO Dr. Srishti Gupta will step down and also leave the Board of Directors. Chairman Jean Paul Clozel will take over as interim CEO. See our latest analysis for Idorsia. The leadership change comes after a mixed period for investors, with the latest CHF3.15 share price sitting against a 1 day share price return of 2.27%, a 30 day share price return of a 14.75% decline, and a very large 1 year total shareholder return of about 3x. However, the 5 year total shareholder return remains deeply negative, which suggests near term momentum has cooled even as sentiment has shifted sharply over the past year. If you are reassessing your exposure to individual names after this kind of volatility, it can help to scan a wider opportunity set using our screener of 95 top founder-led companies So with Idorsia trading at CHF3.15, a sizeable discount to an average analyst price target of CHF4.50 and a long term track record that still includes deep losses, are you seeing a genuine opportunity here or is the market already pricing in future growth? ## Most Popular Narrative: 30% Undervalued The most followed narrative currently places Idorsia’s fair value at CHF4.50 per share, compared with the latest CHF3.15 close. This sets a clear benchmark for how optimistic those assumptions are. > _Optimism regarding the accelerated advancement and eventual commercialization of a broad pipeline (including Fabry disease, chemokine antagonists, and the C. diff vaccine) may be inflating valuation through expectations of long-term multi-asset revenue streams, even though increased cost controls and funding needs persist until 2027 profitability._ _Read the complete narrative._ Want to see what kind of revenue ramp, margin shift, and future earnings multiple are reflected in that CHF4.50 fair value label? Then the full narrative is worth a close read. **Result: Fair Value of CHF4.50 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there are still meaningful risks here, including higher operating expenses and reduced visibility that could increase cash needs and challenge those optimistic fair value assumptions. Find out about the key risks to this Idorsia narrative. ## Next Steps With sentiment clearly split between concern and optimism, it makes sense to look at the underlying numbers yourself and decide quickly where you stand by reviewing the 3 key rewards and 5 important warning signs ## Looking for more investment ideas? If this Idorsia update has sharpened your focus, now is the moment to widen your watchlist and uncover other opportunities before the market moves on without you. - Spot potential value plays early by scanning 229 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying business strength. - Prioritize resilience by checking 283 resilient stocks with low risk scores that score well on balance sheet strength and overall risk, so your portfolio is not built on weak foundations. - Get ahead of the crowd by reviewing screener containing 590 high quality undiscovered gems that have strong fundamentals but limited attention, giving you ideas before they hit everyone’s radar. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ## 相關資訊與研究 - [Managers' transactions announcement according to article 19 MAR](https://longbridge.com/zh-HK/news/281158113.md) - [Grindwell Norton Files Quarterly Demat Compliance Certificate With Stock Exchanges](https://longbridge.com/zh-HK/news/281655672.md) - [Dewa Resumes Trading on Dubai Bourse](https://longbridge.com/zh-HK/news/281521763.md) - [Critical Resources Seeks ASX Quotation for 25 Million New Shares](https://longbridge.com/zh-HK/news/281294861.md) - [Thungela Director Sells R1.67 Million in Shares on JSE](https://longbridge.com/zh-HK/news/281052309.md)